Exelixis (EXEL) Barclays 28th Annual Global Healthcare Conference summary

Strategic overview and financial performance

• Lead molecule CABOMETYX (cabozantinib) underpins commercial and research strategy, approved for multiple cancer types including kidney, liver, thyroid, and neuroendocrine tumors.

• Achieved $2.123 billion in net product sales last year, with guidance for approximately $2.4 billion this year.

• Financial strength supports internal R&D, external investments, and ongoing share buybacks.

• Focused on expanding patient reach and shifting oncology standards of care over the next five years.

Pipeline development and clinical progress

• Zanzalintinib, a next-generation TKI, is in seven pivotal studies with a PDUFA date in December and additional studies planned.

• Internal portfolio includes both small molecules and biotherapeutics targeting solid tumors, especially GI and GU oncology.

• Expansion of commercial organization to support launches in neuroendocrine tumors and colorectal cancer.

• STELLAR-303 and STELLAR-316 studies aim to broaden presence in CRC, including adjuvant settings and ctDNA-positive patients.

Market positioning and external opportunities

• Strategic focus on solid tumors, particularly GI and GU, leveraging expertise in RCC, NET, and CRC.

• External business development guided by the "Cabo lens," prioritizing assets with potential to set new standards of care.

• Disciplined approach to external investments, only pursuing programs with clear differentiation and value.